

# A Critical Systematic Review for Inhaled Corticosteroids on Lung Cancer Incidence: Not Yet Concluded Story

<https://doi.org/10.4046/trd.2022.0084>

ISSN: 1738-3536(Print/)

2005-6184(Online)

Tuberc Respir Dis 2023;86:120-132

Suh-Young Lee, M.D., Ph.D.<sup>1,2</sup>, Soon Ho Yoon, M.D., Ph.D.<sup>3</sup> and Hyunsook Hong, Ph.D.<sup>4</sup>

<sup>1</sup>Department of Internal Medicine, Seoul National University Hospital, Seoul, <sup>2</sup>Institute of Allergy and Clinical Immunology, Seoul National University Medical Research Center, Seoul, <sup>3</sup>Department of Radiology, <sup>4</sup>Medical Research Collaborating Center, Seoul National University Hospital, Seoul, Republic of Korea



Copyright © 2023 The Korean Academy of Tuberculosis and Respiratory Diseases

## Abstract

**Background:** To systematically review studies on inhaled corticosteroids (ICS) and lung cancer incidence in chronic airway disease patients.

**Methods:** We conducted electronic bibliographic searches on OVID-MEDLINE, EMBASE, and the Cochrane Database before May 2020 to identify relevant studies. Detailed data on the study population, exposure, and outcome domains were reviewed.

**Results:** Of 4,058 screened publications, 13 eligible studies in adults with chronic obstructive pulmonary disease (COPD) or asthma evaluated lung cancer incidence after ICS exposure. Pooled hazard ratio and odds ratio for developing lung cancer in ICS exposure were 0.81 (95% confidence interval, 0.64 to 1.02;  $I^2=95.7%$ ) from 10 studies and 1.02 (95% confidence interval 0.50 to 2.07;  $I^2=94.7%$ ) from three studies. Meta-regression failed to explain the substantial heterogeneity of pooled estimates. COPD and asthma were variously defined without spirometry in 11 studies. Regarding exposure assessment, three and 10 studies regarded ICS exposure as a time-dependent and fixed variable, respectively. Some studies assessed ICS use for the entire study period, whereas others assessed ICS use for 6 months to 2 years within or before study entry. Smoking was adjusted in four studies, and only four studies introduced 1 to 2 latency years in their main or subgroup analysis.

**Conclusion:** Studies published to date on ICS and lung cancer incidence had heterogeneous study populations, exposures, and outcome assessments, limiting the generation of a pooled conclusion. The beneficial effect of ICS on lung cancer incidence has not yet been established, and understanding the heterogeneities will help future researchers to establish robust evidence on ICS and lung cancer incidence.

**Keywords:** Asthma; Pulmonary Disease, Chronic Obstructive; Lung Neoplasms; Steroids; Review Literature as Topic

### Address for correspondence

**Suh-Young Lee, M.D., Ph.D.**

Department of Internal Medicine, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea

**Phone** 82-2-2072-4762

**Fax** 82-2-762-9662

**E-mail** suhyoung.lee@snu.ac.kr

**Received** Jun. 30, 2022

**Revised** Oct. 27, 2022

**Accepted** Dec. 27, 2022

**Published online** Jan. 3, 2023



© It is identical to the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>).

## Introduction

Inhaled corticosteroids (ICSs) are milestones in the pharmaceutical treatment of chronic airway diseases. According to asthma treatment guidelines, ICSs are recommended as essential agents for asthma control<sup>1</sup>. The use of ICSs in patients with chronic obstructive

pulmonary disease (COPD) has also been evaluated over the past decade<sup>2</sup>, and they reduced acute exacerbation and improved lung function and quality of life when combined with inhaled bronchodilators in patients with severe COPD<sup>3</sup>. ICSs reduce airway inflammation, especially eosinophilic inflammation<sup>4</sup>.

Studies have reported that the use of ICS may reduce

the risk of lung cancer in airway diseases<sup>5</sup>. These findings are promising; however, further considerations are needed before accepting the results from the following points of view. Most studies were not randomized controlled trials, and the criteria for the study population, exposure, and outcome measures varied. Recently, two similar studies meta-analyzed the outcomes of relevant publications and concluded that ICS reduced the occurrence of lung cancer<sup>6,7</sup>. However, a meta-analysis can only be applied when relevant publications are sufficiently homogeneous in the patients, intervention, comparators, and outcomes (PICO) domain of relevant studies. When candidate publications for pooling are substantially heterogeneous, a mathematical pooling of outcomes can misguide conclusions. Thus, this study aimed to systematically review original studies on ICS and lung cancer incidence in patients with chronic airway diseases, along with provisional pooling, and propose potential standards to be applied to future relevant research.

## Materials and Methods

This systematic review was performed in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline<sup>8</sup>. The study protocol was registered in the International Prospective Register of Systematic Reviews (ID: CRD42019142541). This meta-analysis handled data extracted from relevant published studies and did not require Institutional Review Board approval.

### 1. Search strategy

We searched the OVID-MEDLINE, EMBASE databas-

es, and Cochrane Database of Systematic Reviews to identify relevant original publications dealing with the protective effect of inhaled (keywords: aerosol, nebulizer, inhalation, or with spacer) corticosteroids (keywords: corticosteroid or glucocorticoid or beclomethasone or betamethasone or budesonide or clobetasol or dexamethasone or fluprednisolone or methylprednisolone or triamcinolone) on lung cancer incidence (keywords: lung cancer) in patients with obstructive airway diseases (keywords: COPD or emphysema or asthma). The initial search was conducted on June 18, 2019, limited to English publications, and was updated on May 26, 2020. The authors reviewed the literature to supplement the search strategy of this study.

### 2. Study selection

Two authors independently screened the search results by title and abstract and subsequently reviewed the full-text articles using the following eligibility criteria: (1) adult study population with COPD or asthma; (2) studies or subsets evaluating lung cancer incidence after ICS exposure compared to those not exposed to ICS; and (3) data described in sufficient detail to extract outcomes as the odds ratio (OR) or hazard ratio (HR). We included either prospective or retrospective randomized controlled trials, observational cohort studies, or case-control studies. Case reports, review articles, guidelines, phantom studies, animal studies, letters, editorials, and abstracts were excluded. Any discrepancies between the authors were resolved by consensus.

### 3. Data extraction and quality assessment

Two authors independently extracted data from the included studies using a standardized Excel form. The

**Figure 1.** Flow diagram for study selection.




Table 1. Baseline characteristics of included studies

Study	Country	Study design	Patient collection	Recruitment period	Data source	No. of subjects*	Mean age, yr	Male sex, %	Ever-smoker†
Suissa et al. (2020) <sup>11</sup>	Canada	Cohort study	Retrospective	2000–2014	Provincial population-based database	63,276	71	53	Not available
Husebo et al. (2019) <sup>14</sup>	Norway	Cohort study	Prospective	2006–2009	Multicenter cohort	712	64	60	100% (51%:49%)
Raymakers et al. (2019) <sup>12</sup>	Canada	Cohort study	Retrospective	1999–2007	Provincial population-based database	39,676	71	47	Not available
Lee et al. (2018) <sup>19</sup>	Korea	Nested case-control study‡	Retrospective	2004–2013	Sample cohort of national health insurance	1,325 (265:1,060)	64	78	52% (28%:24%)
Sandelin et al. (2018) <sup>13</sup>	Sweden	Cohort study	Retrospective	1999–2009	Nationwide population-based database	19,894	68	47	Not available
Sorli et al. (2018) <sup>15</sup>	Norway	Cohort study	Prospective	1995–1997	Multicenter cohort	3,041	61	53	Not available (mean pack-year, 22)
Wang et al. (2018) <sup>16</sup>	Taiwan	Cohort study	Retrospective	2001–2005	Claim database of national health insurance§	41,438	50–59 <sup>  </sup>	47	0%
Liu et al. (2017) <sup>20</sup>	Taiwan	Cohort study	Retrospective	1997–2009	Claim database of national health insurance§	13,686	≥60 <sup>  </sup>	0	Not available
Jian et al. (2015) <sup>17</sup>	Taiwan	Nested case-control study‡	Retrospective	2003–2010	Claim database of national health insurance§	3,965 (793:3,172)	72	87	Not available
Kok et al. (2015) <sup>21</sup>	Taiwan	Cohort study	Retrospective	2001–2008	Claim database of national health insurance§	19,849	53	46	No <sup>¶</sup>
Lee et al. (2013) <sup>22</sup>	Korea	Nested case-control study‡	Retrospective	2007–2010	Claim database of national health insurance	46,225 (9,177:37,048)	68	68	Not available
Kiri et al. (2009) <sup>18</sup>	UK	Nested case-control study‡	Retrospective	1989–2003	National general practice research database	1,597 (127:1,470)	71	64	100% (100%:0%)
Parimon et al. (2007) <sup>5</sup>	USA	Cohort study	Prospective	1996–1999	Multicenter cohort	10,474	64	97	88% (34%:54%)

\*Data in parenthesis provides the numbers of lung cancer cases and control. †Studies used the same data source with different recruitment periods and eligibility criteria. ‡Cases and controls indicate patients who developed and did not develop lung cancer, respectively. §Data in the parenthesis indicates the proportion of current and former smokers in order. ¶Age interval was provided instead of mean age. ¶Smoking-related diagnosis based on ICD-9 codes was used as a surrogate for cigarette-smoking history.

following data were extracted: (1) study characteristics; (2) demographic characteristics of the study population; (3) information about how to define ICS users and steroid doses; and (4) outcome information, including the mean or median follow-up period of observation and lung cancer incidence in patients depending on ICS exposure.

The Newcastle-Ottawa Quality Scale for cohort studies was used to assess the quality of the included studies<sup>9</sup>. The scale comprises a maximum of 4 points for the selection domain, 2 points for the comparability domain, and 3 points for the exposure or outcome domain. Scores of 7 or higher and 5–6 indicated high-quality and moderate-quality studies, respectively<sup>10</sup>. Two reviewers independently reviewed the studies, and any discrepancies were resolved through discussion.

#### 4. Meta-analysis

A meta-analysis was performed using the random-effects model, and the analysis was conducted separately by effect measures of HR and OR. Heterogeneity across the studies was assessed with the  $I^2$  statistic, and a meta-regression explored sources of heteroge-

neity. For the HR, which was reported in 10 publications, subgroup analyses were carried out according to indication (asthma vs. COPD), and lengths of the latency period to observe outcome (short- vs. long-term period), and region of studies (Asia vs. non-Asia). The latency period was dichotomized as a short-term period shorter than 1 year versus a long-term period of 1 year or longer in studies that considered the latency between ICS exposure and lung cancer occurrence. In addition, the impact of ICS dose was examined by dichotomizing the dose into low-dose versus high-dose in studies that reported lung cancer occurrence depending upon the ICS dose.


Publication bias was examined using funnel plots and Egger’s test, and the analysis was done using metafor packages in R version 4.1.2 (R Foundation for Statistical Computing, Vienna, Austria).

## Results


### 1. Literature search

Our search initially identified 4,058 publications. Of these references, 13 studies were finally included in our analysis (Figure 1). Among them, 10 studies report-

**Figure 2.** Forest plot in studies assessing the hazard ratio (HR) of inhaled corticosteroid (ICS) exposure. \*The threshold for dichotomizing as low-dose versus high-dose was 500 µg fluticasone equivalents. CI: confidence interval; COPD: chronic obstructive pulmonary disease; RE: random effect.



**Figure 3.** Forest plot in studies assessing the odds ratio (OR) of inhaled corticosteroid (ICS) exposure. \*The threshold for dichotomizing as low-dose versus high-dose was 500 ug fluticasone equivalents. CI: confidence interval; COPD: chronic obstructive pulmonary disease; RE: random effect.



ed HRs for COPD and asthma depending on ICS exposure, whereas the other three studies reported ORs.

### 2. Baseline study characteristics

The median number and age of the study population in the included studies were 13,686 (range, 712 to 63,276) and 64 years (range, 41 to 72), respectively (Table 1). Nine of the studies were cohort studies, and the remaining four were nested case-control studies. Seven and six studies were conducted in Western and Eastern countries, respectively. The study population was recruited mostly between the 1990s and the 2000s in a retrospective manner. Nine studies were based on national or provincial administrative data, three on mul-

tiple hospitals, and one on a sample cohort of national administrative data. Four Taiwanese studies used the same data source, with different recruitment periods and eligibility criteria. The median male proportion of the study population was 47%; however, it varied widely from 0% to 97% across the studies. Most studies could not obtain the smoking history of the study population, and even in studies with available smoking information, the proportion of current smokers was heterogeneous across studies. Four of 13 studies were regarded as high-quality studies based on the Newcastle-Ottawa Quality Scale, whereas the other showed low quality (Supplementary Table S1).

**Table 2.** Subgroup analysis and meta-regression in assessing the hazard ratio

Variable	Subgroup analysis			Meta-regression	
	No. of studies	HR (95% CI)	I <sup>2</sup> *	p-value	I <sup>2</sup> †
Indication				0.1704	93.8%
Asthma	2	1.10 (0.27–4.48)	91.6%		
Chronic obstructive pulmonary disease	8	0.78 (0.65–0.93)	92.0%		
Lengths of latency period‡				0.3564	86.8%
All (short+long)	5	0.88 (0.57–1.36)	92.9%		
Long	4	0.82 (0.63–1.06)	85.4%		
Unknown	1	0.40 (0.17–0.94)	-		
Region				0.6054	95.1%
Asia	4	0.88 (0.49–1.60)	86.3%		
Non-Asia	6	0.78 (0.62–1.00)	95.7%		

\*Heterogeneity within each subgroup. †Percentage of residual heterogeneity among the unaccounted variance. ‡The latency period was dichotomized as a short-term period shorter than 1 year versus a long-term period 1 year longer in studies that considered the latency between inhaled corticosteroid exposure and lung cancer occurrence. HR: hazard ratio; CI: confidence interval.

**Figure 4.** Forest plot of subgroup analysis according to inhaled corticosteroid (ICS) indication, outcome interval, and continents. \*The latency period was dichotomized as a short-term period shorter than 1 year versus a long-term period 1 year longer in studies that considered the latency between ICS exposure and lung cancer occurrence. HR: hazard ratio; CI: confidence interval; COPD: chronic obstructive pulmonary disease.




Table 3. Eligibility criteria of included studies

Study	Disease	Age, yr	Inclusion criteria		Exclusion criteria			
			Patient selection	New drug diagnosis	Previous history of cancer	Former ICS users	Asthma*	Other
Suissa et al. (2020) <sup>11</sup>	COPD	≥50	Prescription-based (long-acting BD ≥3 times a year)	New drug users	Lung cancer	Yes	No	Follow-up <1 year <sup>†</sup>
Husebo et al. (2019) <sup>14</sup>	COPD	40–76	Physician-diagnosed or spirometry-based <sup>‡</sup>	No	Any cancer	Not mentioned	Yes	Active inflammatory disorders, COPD exacerbation within 4 weeks of entry
Raymakers et al. (2019) <sup>12</sup>	COPD	≥50	Prescription-based (short-acting BD ≥3 times a year)	New drug users	Lung cancer	Not mentioned	Subgroup analysis	Follow-up <1 year <sup>†</sup> , lung cancer within a year after entry
Lee et al. (2018) <sup>19</sup>	COPD	30–89	ICD code & prescription-based (inhaled drugs ≥twice)	New diagnosis & new drug users	Lung cancer	Yes	No	
Sandelin et al. (2018) <sup>13</sup>	COPD	No	ICD code-based (≥once)	No	Not mentioned	Not mentioned	No	
Sorli et al. (2018) <sup>15</sup>	Chronic airway inflammation	≥20	Patient-reported (cough/sputum for 3 months) or spirometry-based <sup>§</sup>	No	Lung cancer (before 2002)	Not mentioned	Not applicable	
Wang et al. (2018) <sup>16</sup>	Asthma	40–70	ICD code-based (≥once [ward] or ≥3 times in 3 months [outpatient])	New diagnosis	Lung cancer	Yes	Not applicable	Lung cancer within 2 years after entry <sup>†</sup> , smokers
Liu et al. (2017) <sup>20</sup>	COPD	≥40	ICD code-based (≥once [ward] or ≥twice [outpatient] a year)	New diagnosis	Lung cancer	Not mentioned	Yes	
Jian et al. (2015) <sup>17</sup>	COPD, asthma	≥20	ICD code-based (≥once)	New diagnosis	Lung cancer	Not mentioned	Not applicable	Missing data, lung cancer within 2 years after entry <sup>†</sup>
Kok et al. (2015) <sup>21</sup>	Asthma	≥20	ICD code-based (≥3 times a year)	New diagnosis	Any cancer	Yes	Not applicable	Missing data, ICD code <3 times a year
Lee et al. (2013) <sup>22</sup>	COPD, asthma	20–120	Prescription-based (inhaled drugs for ≥30 days)	New drug users	Any cancer	Not mentioned	Not applicable	

Table 3. Continued

Study	Disease	Age, yr	Inclusion criteria		Exclusion criteria			
			Patient selection	New diagnosis	Previous history of cancer	Former ICS users	Asthma*	Other
Kiri et al. (2009) <sup>18</sup>	COPD	≥50	Physician-diagnosed (ex-smoker COPD) & prescription-based (inhaled drugs within 6 months of enrollment)	New diagnosis & new drug users	Lung cancer	Not mentioned	Not mentioned	Cystic fibrosis
Parimon et al. (2007) <sup>5</sup>	COPD	≥40	Physician-diagnosed or patient-reported (chronic lung disease) or prescription-based (BD within 1 year before enrollment)	No	Lung cancer	Not mentioned	Not mentioned	

\*Age threshold might help exclude asthmatic patients who develop asthma at a young age. <sup>†</sup>Inhaler drugs included ICS, BD, and combination of ICS and BD. <sup>‡</sup>A post-bronchodilation test with forced expiratory volume in 1 second/forced vital capacity ratio <0.7, and forced expiratory volume in 1 second <80% of predicted values. <sup>§</sup>Forced expiratory volume in 1 second <70% of predicted values. ICS: inhaled corticosteroid; COPD: chronic obstructive pulmonary disease; BD: bronchodilator; ICD: International Classification of Diseases.

### 3. Meta-analysis

The pooled HR for developing lung cancer in ICS exposure from 10 studies was 0.81 (95% confidence interval [CI], 0.64 to 1.02;  $I^2=95.7\%$ ) (Figure 2). The pooled OR from three studies was 1.02 (95% CI, 0.50 to 2.07;  $I^2=94.7\%$ ) (Figure 3). The pooled HR for low-dose ICS was 0.91 (95% CI, 0.85 to 0.98) (Figure 2), and the results were not significantly different between the three studies ( $I^2=0.0\%$ ), but for high-dose ICS, the pooled HR was 0.67 (95% CI, 0.30 to 1.54) and the results were significantly heterogeneous between the three studies ( $I^2=82.6\%$ ).

Subgroup analyses (Table 2, Figure 4) showed that the estimated pooled HR from two asthma studies was 1.10 (95% CI, 0.27 to 4.48), and the heterogeneity between the two studies was considerable, with  $I^2=91.6\%$ . The pooled HR from eight COPD studies was 0.78 (95% CI, 0.65 to 0.93), and the heterogeneity between the studies was also substantial, with  $I^2=92.0\%$ . Meanwhile, as a result of meta-regression evaluating the difference in HR according to the indication subgroup (Table 2), there was no statistically significant difference as  $p=0.1704$ , and the heterogeneity was not unexplained by indications. There was also no statistically significant difference in the analysis results according to the outcome interval or the study region.

There was no obvious publication bias based on the funnel plot (Supplementary Figure S1) and Egger test ( $p=0.4777$ ) in the studies assessing the HR of ICS exposure.

### 4. Eligibility criteria

Of the 13 studies, eight studies targeted COPD and two studies targeted asthma exclusively, whereas the others targeted both COPD and asthma (Table 3). The eligibility criteria for the study population varied across the studies. Some of the studies applied a minimum age varying from 20 to 50 years, while others did not. Most of the included studies enrolled patients with a new diagnosis or new ICS users, but spirometry was used in only two of the studies to include patients with targeted lung disease. Therefore, prescription-based, International Classification of Diseases (ICD) diagnosis code-based, physician-driven, or patient-alleged diagnoses have been heterogeneously applied. The minimum requisite number for diagnosis or prescription also varied from once to thrice during a varying pre-enrollment or study period from 3 months to 1 year. The exclusion criteria mainly included patients with previous lung or any cancers, former ICS use, asthma, and a short follow-up period. Patients with previous lung or any cancers were consistently excluded from

the included studies, but those with former ICS use, asthma, and a short follow-up period were handled heterogeneously.

### 5. Exposure assessment

Three studies<sup>11-13</sup> regarded ICS exposure as a time-dependent variable, whereas the other 10 studies<sup>5,14-22</sup> regarded ICS exposure as a fixed variable (Table 4). The median proportion of ICS users was 30% ranging from 5% to 71%. The 10 studies applied different frequencies and durations for defining ICS users. Controls were never-ICS users in some studies<sup>20,21</sup>, while they were both irregular ICS users and never-ICS users in other studies<sup>5,15,16,19,22</sup>. Regarding the period of ICS use, some studies assessed ICS use for the entire study period, whereas others assessed ICS use for 6 months to 2 years within or before study entry. The top three ICS drugs for assessing ICS use were beclomethasone, budesonide, and fluticasone; however, other ICS drugs were also included. Some of the studies provided the median daily or cumulative dose of fluticasone equivalents, which were approximately 500 µg and 39,480–90,000 µg, respectively.

### 6. Outcome assessment

The median cancer incidence and follow-up periods were 4% and 3.9 years, respectively, although five studies did not provide a median follow-up period of the study population (Table 5). Among ICS users compared to controls, 12 studies assessed the hazard risk for lung cancer development, and two studies assessed the OR. Nine studies found an association between ICS use and reduced development of lung cancer, whereas four studies did not find such an association. Adjusted confounders were heterogeneous across the studies, and smoking was adjusted in four of the 13 studies. Only four studies introduced 1 to 2 latency years in their main or subgroup analysis, assuming that ICS can be biologically effective in preventing lung cancer development at least 1 to 2 years before the establishment of a lung cancer diagnosis. In addition, only four studies avoided immortal time bias by not allocating the unexposed period to ICS as the exposure period.

## Discussion

This critical systematic review highlighted the extreme heterogeneity of studies on the protective effects of ICS against lung cancer development. We provisionally meta-analyzed HRs and ORs for developing lung cancer in ICS exposure: the pooled HR, 0.81 (95% CI, 0.64 to 1.02;  $I^2=95.7%$ ); the pooled OR, 1.02 (95% CI, 0.50 to

2.07;  $I^2=94.7%$ ). The protective effect of ICS was inconsistent between HR and OR, and the pooled HR and OR both had substantial heterogeneity that potential sources of heterogeneities could not explain on meta-regression. This heterogeneity cannot be handled beyond mathematical pooling using a random-effects model, as heterogeneity exists in all domains, including study characteristics, eligibility criteria, exposures, and outcome assessments. Further, we would like to discuss how these heterogeneities were observed in the studies included in the analysis and how they can affect the study outcome.

First, the eligibility criteria for selecting the study population varied across studies. In addition, smoking is the most influential carcinogen for the development of lung cancer<sup>23</sup> but was not adjusted in a considerable proportion of the studies<sup>11-13,15,17,20,22</sup>. Lung cancer generally develops after 40 years; however, five studies included patients aged <40 years<sup>15,17,19,21,22</sup>. In particular, it was different for each study whether it included only newly diagnosed airway diseases/new ICS users and whether it enrolled all patients with airway diseases using ICS without any restrictions. Assuming that the duration of the disease and the period of exposure to the medication affect the incidence of lung cancer, the effects may be underestimated or overestimated if the degree of exposure is not accurately measured. Therefore, to obtain proper outcomes, the treatment duration from personal first ICS should be defined as exposure only for patients who were diagnosed with airway diseases for the first time.

Second, the studies assessed the degree of ICS exposure differently. Some studies assessed ICS exposure during the entire study period, whereas others assessed ICS exposure in a limited time window before or during the study period. While there have been studies that simply used the absolute dose as the criterion for ICS use, there have also been studies that applied weights for the duration of ICS use. In principle, the ICS dose with weights for the duration could quantify ICS exposure to each patient more accurately than the absolute dose. In addition, the confirmation of actual ICS use showed various aspects. Most studies identified the regular use of ICS, but some studies only checked prescription records, which can affect the results of the analysis.

Finally, in terms of the outcome measure, the latency period from the initiation of observation is varyingly applied across studies. Some studies have placed a latency period of 1 to 2 years, while other lack this period. Considering the process of lung cancer development, it is challenging to prove the causality of the occurrence



Table 4. Exposure assessment of included studies

Study	ICS exposure	Proportion of ICS users*	Definition of ICS users	Definition of non-ICS users	Period of ICS use	ICS drugs	Median ICS dose†
Suissa et al. (2020) <sup>11</sup>	Time-dependent variable	63% (40,164/63,276)	Person time under ICS exposure	Person time of non-ICS users & before 1st ICS exposure	During the study period	Becl., Budeso., Triam, Flutica., Cicleso., Fluniso.	Daily dose, 0–500 µg‡
Husebo et al. (2019) <sup>14</sup>	Fixed variable	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned	Not mentioned
Raymakers et al. (2019) <sup>12</sup>	Time-dependent variable	71% (28,314/39,676)	Person time under ICS exposure	Person time of non-ICS users & before 1st ICS exposure	During the study period	Not mentioned	Daily dose, 640 µg
Lee et al. (2018) <sup>19</sup>	Fixed variable	63% (833/1,325)	ICS prescription ≥twice	No ICS prescription or ICS prescription once	During the study period	Becl., Budeso., Triam, Flutica., Cicleso., Fluniso.	Cumulative dose, 90,000 µg
Sandelin et al. (2018) <sup>13</sup>	Time-dependent & fixed variables	Not mentioned	Not mentioned	Not mentioned	During 2 years before entry	Not mentioned	Not mentioned
Sorfi et al. (2018) <sup>15</sup>	Fixed variable	36% (1,095/3,041)	Patient-alleged ever regular ICS users	No ICS users or ICS irregular users	Lifetime	Becl., Budeso., Flutica.	Not mentioned
Wang et al. (2018) <sup>16</sup>	Fixed variable	10% (4,210/41,438)	ICS prescription >28 days/month in ≥4 consecutive months	No ICS prescription or ICS prescription <4 consecutive months	During the study period	Becl., Budeso., Triam, Flutica., Fluniso.	Not mentioned
Liu et al. (2017) <sup>20</sup>	Fixed variable	9% (1,290/13,686)	ICS prescription for >28 days	No ICS prescription	During the study period	Budeso., Flutica.	Cumulative dose, 39,480 µg
Jian et al. (2015) <sup>17</sup>	Fixed variable	12% (492/3,965)	Not mentioned	Not mentioned	During 2 years before entry	Becl., Budeso., Flutica., Cicleso.,	Cumulative dose, 90,000 µg
Kok et al. (2015) <sup>21</sup>	Fixed variable	11% (2,117/19,849)	ICS prescription ≥6 times a year	No ICS prescription	During the study period	Becl., Budeso., Flutica.	Not specified
Lee et al. (2013) <sup>22</sup>	Fixed variable	30% (14,017/46,225)	ICS prescription for ≥30 days	No ICS prescription or ICS prescription <30 days	During 1 year before entry	Becl., Budeso., Triam, Flutica., Cicleso., Fluniso.	Cumulative dose, 90,000 µg
Kiri et al. (2009) <sup>18</sup>	Fixed variable	74% (1,176/1,597)	ICS prescription ≥3 times	-	Within 6 months of entry	Not mentioned	Not specified
Parimon et al. (2007) <sup>5</sup>	Fixed variable	5% (517/10,474)	≥80% adherent	No ICS prescription & <80% adherent	During the 180 days before entry	Becl., Triam, Flutica., Fluniso.	Daily dose, 300 µg

\*Data in the parenthesis indicate the numbers of ICS users and total study population in order. †The median ICS dose was summarized as the dose of fluticasone equivalents. ‡ICS dose was provided as dose intervals instead of median dose, and the median dose seemed close to 500 µg. ICS: inhaled corticosteroid; Becl.: beclomethasone; Budeso.: budesonide; Triam.: triamcinolone; Flutica.: fluticasone; Cicleso.: ciclesonide; Fluniso.: flunisolide.

Table 5. Outcome assessment of included studies

Study	Lung cancer incidence, %	Follow-up duration, yr	Statistics	Summary	Adjusted confounders	Latency between ICS exposure and lung cancer occurrence, yr*	Immortal time bias†
Suissa et al. (2020) <sup>11</sup>	5.9 <sup>‡</sup>	Mean, 4.7	Time-dependent Cox regression	aHR, 1.01 (0.94–1.08)	Age, sex, comorbidities	1	Adjusted
Husebo et al. (2019) <sup>14</sup>	4.4	Mean, 9	Cox regression	aHR, 0.40 (0.17–0.93)	Age, sex, smoking, body composition, emphysema	No	No
Raymakers et al. (2019) <sup>12</sup>	2.5 <sup>‡</sup>	Mean, 5.2	Cox regression	aHR, 0.70 (0.61–0.80)	Age, sex, region, income, hospitalization, comorbidities, medication	1	Adjusted
Lee et al. (2018) <sup>19</sup>	2.5	Mean, 4	Cox regression	aHR, 0.74 (0.57–0.96)	Income, smoking, body mass index, comorbidities	No	No
Sandelin et al. (2018) <sup>13</sup>	3.0	Not mentioned	Cox regression	aHR, 0.52 (0.37–0.73)	Age, asthma, medication	No	Potentially adjusted
Sorli et al. (2018) <sup>15</sup>	3.4	Not mentioned	Cox regression	aHR, 0.97 (0.61–1.54)	Age, sex, smoking, forced expiratory volume in one second	No	No
Wang et al. (2018) <sup>16</sup>	1.8	Not mentioned	Cox regression	aHR, 0.42 (0.31–0.56)	Age, sex, allergic status, and comorbidities	2	No
Liu et al. (2017) <sup>20</sup>	2.2	Median, 9.8	Cox regression	aHR, 0.45 (0.21–0.96) <sup>§</sup>	Age, income, comorbidities	No	No
Jian et al. (2015) <sup>17</sup>	20.0	Mean, 3.9	Conditional logistic regression	aOR, 2.09 (1.52–2.88) for low ICS & 1.88 (1.32–2.66) for high ICS	Region, income, health care utility, comorbidities, aspirin use	2	No
Kok et al. (2015) <sup>21</sup>	6.0	Mean, 3.5	Cox regression	aHR, 2.23 (1.31–3.79)	Age, sex, comorbidities, smoking-related diagnoses, asthma medication	No	Adjusted
Lee et al. (2013) <sup>22</sup>	24.8	Not mentioned	Conditional logistic regression	aOR, 0.79 (0.69–0.90)	Bronchodilator and oral steroid use	No	No
Kiri et al. (2009) <sup>18</sup>	8.0	Not mentioned	Conditional logistic regression	aOR <sup>  </sup> , 0.64 (0.42–0.98) for ICS & 0.50 (0.27–0.90) for LABA/ICS	Duration of both smoking cessation and COPD, comorbidities, medication	No	No
Parimon et al. (2007) <sup>5</sup>	4.0 (2.4 <sup>‡</sup> )	Median 3.8	Cox regression	aHR, 0.39 (0.16–0.96) <sup>¶</sup> & 0.41 (0.13–1.31) <sup>¶</sup>	Age, smoking, history of malignancy other than skin cancer, comorbidities, bronchodilator use	1 (subgroup analysis)	No

\*The latency indicated the minimum interval that ICS can affect lung cancer development. The authors assumed that ICS might not affect a biological plausibility of lung cancer within 1 year before the establishment of lung cancer. †The immortal time bias occurs when unexposed period to ICS (before the first ICS exposure) is assigned exposed period. The bias can overestimate time considered as exposed. ‡The authors excluded lung cancer within 1 year of the index date. §aHR was for ICS users who used a cumulative ICS dose of 39,480 µg or greater. ¶The risk for lung cancer development was described as HR in the manuscript, but their statistical analysis was a conditional regression analysis, implying that the assessed risk corresponded to OR rather than HR. ¶aHR was for ICS users who used a daily ICS dose of 1,200 µg or greater. ICS: inhaled corticosteroid; aHR: adjusted hazard ratio; aOR: adjusted odds ratio; COPD: chronic obstructive pulmonary disease; LABA: long-acting beta-agonist.

of lung cancer immediately after a short exposure period. Therefore, ensuring a minimum latency period is essential. There were significant differences in the incidence rate of lung cancer between the studies, which could be biased. In addition, it was observed that the highest risk factor was not properly controlled because smoking history was not included as an adjusted confounder due to the methodological limitations of the study.

The mechanism of action of ICS in the development of lung cancer has not been clearly described. Although chronic airway inflammatory diseases, including COPD and lung cancer, affect the lungs distinctly, airflow obstruction in COPD has been reported as a risk factor for lung cancer independent of smoking<sup>24-28</sup>. Both programmed aging and non-programmed death are presumed to be key common mechanisms in developing lung cancer and COPD<sup>29-31</sup>. Several genetic factors have been reported to be commonly involved in COPD and lung cancer<sup>32-34</sup>. From the acquired perspective, the hypothesis that specific inflammatory microenvironments expressed in chronic airway diseases form the lung cancer-prone condition is the most convincing. Specifically, the Th1 inflammatory microenvironment promotes the generation of reactive oxygen species<sup>35</sup> and activates transcription factors such as nuclear factor kappa B (NF- $\kappa$ B) and activator protein 1 (AP-1)<sup>36</sup>, leading to carcinogenesis. In addition, the increased secretion of myeloperoxidase (MPO), neutrophil elastase, and matrix metalloproteinase 9 (MMP9) induced by interleukin 17 provides an environment for promoting tumor growth<sup>37,38</sup>. Although ICS has a major effect on controlling Th2 inflammation, it can be estimated that the role of ICS in regulating the inflammatory process may inhibit carcinogenesis.

In conclusion, studies published to date on ICS and lung cancer incidence had heterogeneous study populations, study designs, exposure definitions, and outcome assessments to generate a pooled conclusion. Understanding these heterogeneities will help future researchers establish robust evidence of ICS and lung cancer incidence.

## Authors' Contributions

Conceptualization: Lee SY, Yoon SH. Methodology: Lee SY, Yoon SH, Hong H. Formal analysis: Lee SY, Yoon SH, Hong H. Data curation: Lee SY, Yoon SH. Project administration: Lee SY. Resources: Lee SY. Software: Lee SY, Hong H. Supervision: Lee SY. Validation: Lee SY, Yoon SH, Hong H. Visualization: Lee SY, Yoon SH. Investigation: Lee SY, Yoon SH, Hong H. Writing - original draft

preparation: Lee SY, Yoon SH, Hong H. Writing - review and editing: Lee SY, Yoon SH, Hong H. Approval of final manuscript: all authors.

## Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

## Funding

No funding to declare.

## Supplementary Material

Supplementary material can be found in the journal homepage (<http://www.e-trd.org>).

Supplementary Table S1. Quality assessment of the included studies.

Supplementary Figure S1. Funnel plots for studies assessing the hazard ratio (HR) of inhaled corticosteroid exposure.

## References

1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention (2021 update). Fontana: GINA; 2021.
2. Tashkin DP, Strange C. Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy? *Int J Chron Obstruct Pulmon Dis* 2018;13:2587-601.
3. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. *N Engl J Med* 2007;356:775-89.
4. Tashkin DP, Wechsler ME. Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis* 2018;13:335-49.
5. Parimon T, Chien JW, Bryson CL, McDonnell MB, Udris EM, Au DH. Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2007;175:712-9.
6. Lin P, Fu S, Li W, Hu Y, Liang Z. Inhaled corticosteroids and risk of lung cancer: a systematic review and meta-analysis. *Eur J Clin Invest* 2021;51:e13434.
7. Ge F, Feng Y, Huo Z, Li C, Wang R, Wen Y, et al. Inhaled corticosteroids and risk of lung cancer among chronic obstructive pulmonary disease patients: a comprehensive analysis of nine prospective cohorts. *Transl Lung Cancer Res* 2021;10:1266-76.
8. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA

- Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Int J Surg* 2010;8:336-41.
9. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol* 2010;25:603-5.
  10. Suh YJ, Yoon SH, Hong H, Hahn S, Kang DY, Kang HR, et al. Acute adverse reactions to nonionic iodinated contrast media: a meta-analysis. *Invest Radiol* 2019;54:589-99.
  11. Suissa S, Dell'Aniello S, Gonzalez AV, Ernst P. Inhaled corticosteroid use and the incidence of lung cancer in COPD. *Eur Respir J* 2020;55:1901720.
  12. Raymakers AJN, Sadatsafavi M, Sin DD, FitzGerald JM, Marra CA, Lynd LD. Inhaled corticosteroids and the risk of lung cancer in COPD: a population-based cohort study. *Eur Respir J* 2019;53:1801257.
  13. Sandelin M, Mindus S, Thuresson M, Lisspers K, Stallberg B, Johansson G, et al. Factors associated with lung cancer in COPD patients. *Int J Chron Obstruct Pulmon Dis* 2018;13:1833-9.
  14. Husebo GR, Nielsen R, Hardie J, Bakke PS, Lerner L, D'Alessandro-Gabazza C, et al. Risk factors for lung cancer in COPD: results from the Bergen COPD cohort study. *Respir Med* 2019;152:81-8.
  15. Sorli K, Thorvaldsen SM, Hatlen P. Use of inhaled corticosteroids and the risk of lung cancer, the HUNT Study. *Lung* 2018;196:179-84.
  16. Wang JJ, Liang WM, Wu TN, Karmaus WJJ, Hsu JC. Inhaled corticosteroids may prevent lung cancer in asthma patients. *Ann Thorac Med* 2018;13:156-62.
  17. Jian ZH, Huang JY, Lin FC, Nfor ON, Jhang KM, Ku WY, et al. The use of corticosteroids in patients with COPD or asthma does not decrease lung squamous cell carcinoma. *BMC Pulm Med* 2015;15:154.
  18. Kiri VA, Fabbri LM, Davis KJ, Soriano JB. Inhaled corticosteroids and risk of lung cancer among COPD patients who quit smoking. *Respir Med* 2009;103:85-90.
  19. Lee YM, Kim SJ, Lee JH, Ha E. Inhaled corticosteroids in COPD and the risk of lung cancer. *Int J Cancer* 2018;143:2311-8.
  20. Liu SF, Kuo HC, Lin MC, Ho SC, Tu ML, Chen YM, et al. Inhaled corticosteroids have a protective effect against lung cancer in female patients with chronic obstructive pulmonary disease: a nationwide population-based cohort study. *Oncotarget* 2017;8:29711-21.
  21. Kok VC, Horng JT, Huang HK, Chao TM, Hong YF. Regular inhaled corticosteroids in adult-onset asthma and the risk for future cancer: a population-based cohort study with proper person-time analysis. *Ther Clin Risk Manag* 2015;11:489-99.
  22. Lee CH, Hyun MK, Jang EJ, Lee NR, Kim K, Yim JJ. Inhaled corticosteroid use and risks of lung cancer and laryngeal cancer. *Respir Med* 2013;107:1222-33.
  23. Loeb LA, Ernster VL, Warner KE, Abbotts J, Laszlo J. Smoking and lung cancer: an overview. *Cancer Res* 1984;44(12 Pt 1):5940-58.
  24. de Torres JP, Marin JM, Casanova C, Cote C, Carrizo S, Cordoba-Lanus E, et al. Lung cancer in patients with chronic obstructive pulmonary disease: incidence and predicting factors. *Am J Respir Crit Care Med* 2011;184:913-9.
  25. Skillrud DM, Offord KP, Miller RD. Higher risk of lung cancer in chronic obstructive pulmonary disease: a prospective, matched, controlled study. *Ann Intern Med* 1986;105:503-7.
  26. Calabro E, Randi G, La Vecchia C, Sverzellati N, Marchiano A, Villani M, et al. Lung function predicts lung cancer risk in smokers: a tool for targeting screening programmes. *Eur Respir J* 2010;35:146-51.
  27. Wasswa-Kintu S, Gan WQ, Man SF, Pare PD, Sin DD. Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis. *Thorax* 2005;60:570-5.
  28. Mannino DM, Aguayo SM, Petty TL, Redd SC. Low lung function and incident lung cancer in the United States: data from the first National Health and Nutrition Examination Survey follow-up. *Arch Intern Med* 2003;163:1475-80.
  29. Caramori G, Adcock IM, Casolari P, Ito K, Jazrawi E, Tsaprouni L, et al. Unbalanced oxidant-induced DNA damage and repair in COPD: a link towards lung cancer. *Thorax* 2011;66:521-7.
  30. MacNee W. Is chronic obstructive pulmonary disease an accelerated aging disease? *Ann Am Thorac Soc* 2016;13 Suppl 5:S429-37.
  31. Frias C, Garcia-Aranda C, De Juan C, Moran A, Ortega P, Gomez A, et al. Telomere shortening is associated with poor prognosis and telomerase activity correlates with DNA repair impairment in non-small cell lung cancer. *Lung Cancer* 2008;60:416-25.
  32. Anzalone G, Arcoletto G, Bucchieri F, Montalbano AM, Marchese R, Albano GD, et al. Cigarette smoke affects the onco-suppressor DAB2IP expression in bronchial epithelial cells of COPD patients. *Sci Rep* 2019;9:15682.
  33. Zhao B, Han H, Chen J, Zhang Z, Li S, Fang F, et al. MicroRNA let-7c inhibits migration and invasion of human non-small cell lung cancer by targeting ITGB3 and MAP4K3. *Cancer Lett* 2014;342:43-51.
  34. Yang P, Sun Z, Krowka MJ, Aubry MC, Bamlet WR, Wampfler JA, et al. Alpha1-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk. *Arch Intern Med* 2008;168:1097-103.

35. Haqqani AS, Sandhu JK, Birnboim HC. Expression of interleukin-8 promotes neutrophil infiltration and genetic instability in mutatact tumors. *Neoplasia* 2000;2:561-8.
36. Rahman I, Adcock IM. Oxidative stress and redox regulation of lung inflammation in COPD. *Eur Respir J* 2006;28: 219-42.
37. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. *Nat Immunol* 2005;6:1133-41.
38. Shapiro SD, Goldstein NM, Houghton AM, Kobayashi DK, Kelley D, Belaaouaj A. Neutrophil elastase contributes to cigarette smoke-induced emphysema in mice. *Am J Pathol* 2003;163:2329-35.